Cuspa

Transcatheter Treatment for Valve Insufficiency

Health Tech & Life Sciences
Private
Follow

Company Overview

Generating analyst summary…

Log in to access full profile

Company Intelligence Q&A

What is Cuspa's core product?
Cuspa's core product is CUSPER, an artificial cusp designed for the transcatheter treatment of aortic valve insufficiency. It attaches to the native aortic valve cusp using a nitinol grasper to restore proper valve function.
When was Cuspa founded?
Cuspa was founded in August 2019 by Yair Feld.
What is Cuspa's current product development stage?
Cuspa's CUSPER device is currently in the clinical trial stage, with pre-clinical studies on pigs having been carried out to optimize its performance.
What is the primary medical condition Cuspa aims to address?
Cuspa aims to treat aortic valve insufficiency (AI), a heart disorder where the aortic valve does not close properly, causing blood to flow backward into the heart.
Log in to access full profile